<SEC-DOCUMENT>0001193125-12-246953.txt : 20120524
<SEC-HEADER>0001193125-12-246953.hdr.sgml : 20120524
<ACCEPTANCE-DATETIME>20120524154659
ACCESSION NUMBER:		0001193125-12-246953
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120524
FILED AS OF DATE:		20120524
DATE AS OF CHANGE:		20120524

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		12867236

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d358641d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 6-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dated May&nbsp;24, 2012 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number 001-35428 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name as Specified in its Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Translation of Registrant&#146;s Name) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Level 7, 151 Macquarie Street </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sydney, 2000 New South Wales, Australia
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form
20-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check
mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If &#147;Yes&#148; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May&nbsp;24, 2012 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prima BioMed Ltd</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Martin Rogers</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin Rogers</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:75pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Exhibit</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated May 24, 2012, titled &#147;Prima BioMed Announces Changes to the Board and Senior
Management&#148;.</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d358641dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g358641g57z91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASX/Media Release (Code: ASX:PRR; NASDAQ:PBMD) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>24&nbsp;May 2012 </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRIMA BIOMED ANNOUNCES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CHANGES TO THE BOARD AND SENIOR MANAGEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD) (&#147;Prima&#148; or the &#147;Company&#148;) advises of the following changes to senior management and the board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Chief Executive Officer, Martin Rogers will step down effective 31&nbsp;August 2012. Mr.&nbsp;Rogers will remain on Prima&#146;s board
as a non-executive director from 1&nbsp;September 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Matthew Lehman, the Company&#146;s Chief Operating Officer, will assume the CEO role
effective 1&nbsp;September 2012. Mr.&nbsp;Lehman will join the Prima board of directors effective immediately. Mr.&nbsp;Lehman will be the Acting CEO during the period of Mr.&nbsp;Rogers&#146; nuptial leave until the end of July 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">These changes are intended to facilitate CVac&#146;s continued clinical and regulatory development, and position Prima for the Company&#146;s next stage
of growth. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prima Chairman Lucy Turnbull AO said: &#147;On behalf of the Company, we would like to thank Martin Rogers for his tireless work
in transforming Prima over the past 4 1/2 years. Under his leadership, Martin consolidated Prima&#146;s research activities to focus on development of CVac, he brought together a strong management team and board of directors, and he has overseen the
globalization of Prima&#146;s development activities with key operations in the USA and Germany. As Martin transitions out of active management, he leaves the Company in a strong financial position with significant opportunity for growth. On behalf
of everyone at Prima, we thank Martin for his service and wish him well in his future endeavours.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr Rogers said: &#147;It has been an
honour to serve patients, the medical community, and our shareholders over the past 4 1/2 years. I have every confidence that the Prima team is an excellent position to capitalise on the success the Company has achieved to date, in both the clinical
programs for CVac&#153; and at the corporate level. Prima has a world class management team and it has been a privilege to work with such a talented group. I would like to acknowledge the outstanding support of the board and all the Prima team
during my tenure as CEO.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms Turnbull continued: &#147;We are confident that Matthew Lehman&#146;s extensive experience in product
development and clinical trial execution will serve Prima well in the next stages of the Company&#146;s growth. After successfully leading Prima&#146;s operations and clinical development for over 2 years, he is a natural choice for this role.&#148;
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prima
BioMed Ltd</B>, Level 7, 151 Macquarie Street, Sydney NSW 2000 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>www.primabiomed.com.au</U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ABN: 90 009 237 889 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As Mr.&nbsp;Lehman transitions into the CEO role, he will relocate from Germany to the San Francisco Bay
Area, where Prima plans to concentrate its longer-term operational expansion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On his appointment as an executive director and being named CEO
designate, Mr.&nbsp;Lehman said: &#147;It gives me great pleasure to join Prima&#146;s board and to be named CEO designate after having worked closely with our directors for the past several years. I would like to thank Martin for his support, and
the enthusiasm and passion he brought to Prima. As the Company&#146;s next CEO, I look forward to working with the Prima management team and the board to build upon the strong foundation set by Martin.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Lehman continued: &#147;I also look forward to spending significant time in Australia meeting with shareholders, while maintaining a strong link
to the major US and European markets. As a truly global organization, we will have a good geographic representation among our board and our senior management.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Also effective today, Dr.&nbsp;Neil Frazer has stepped down from his position as an executive director on the board. This move assures consistency with the Corporate Governance Principles and
Recommendations of the Australian Securities Exchange such that the independent non-executive directors maintain a majority on the Company board. The board thanks Neil for his outstanding contributions as a board member and looks forward to a
continued strong working relationship in his senior management role as Chief Medical Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company advises of further updates to
senior management. Dr.&nbsp;Sharron Gargosky has been promoted to Chief Technical Officer. Dr.&nbsp;Gargosky, based on the West Coast of the US, is charged with leading the scientific and technical development of CVac globally. Marc Voigt has been
promoted to General Manager of the German subsidiary and Chief Business Officer of the Company. Mr.&nbsp;Voigt will be globally responsible for coordinating investor relations and driving business development. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australia Investor/Media:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;James Moses, Mandate Corporate </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">+61 (0)&nbsp;420 991 574; <U>james@mandatecorporate.com.au</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">USA Investor/Media: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Kathy Galante, Burns McClellan Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">+1
(212)&nbsp;213-0006; <U>kgalante@burnsmc.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Europe Investor/Media: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Axel M&uuml;hlhaus, edicto GmbH </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">+49 (0)&nbsp;69 905505-52; <U>amuehlhaus@edicto.de</U>
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prima
BioMed Ltd</B>, Level 7, 151 Macquarie Street, Sydney NSW 2000 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>www.primabiomed.com.au</U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ABN: 90 009 237 889 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Matthew Lehman </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Lehman joined Prima as Chief Operating Officer on 1&nbsp;February 2010. He has since played a leading role in the clinical development of CVac as well as the executive management of the Company.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to joining Prima, Mr.&nbsp;Lehman was the Chief Operating Officer for SPRI Clinical Trials, an international contract research
organization servicing the biotechnology and pharmaceutical industries, where he led successful expansion of the business in the emerging Eastern European markets. Over the years, Mr.&nbsp;Lehman has held various positions of increasing
responsibility in clinical development and biotechnology operations, with extensive experience managing large teams across the United States and Europe. He has been involved in hundreds of R&amp;D programs in oncology and other therapeutic areas,
including key development contributions to a number of now FDA- and EMA-approved products. Mr.&nbsp;Lehman is active in a number of industry organizations with a strong interest in optimizing clinical research and efficient deployment of R&amp;D
expenditures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Lehman earned a BA from the University of Louisville and an MS from Columbia University. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Prima BioMed </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prima BioMed is a
global biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and
maximize value to shareholders. Prima&#146;s lead product is CVac&#153;, an autologous dendritic cell product currently in clinical trials for ovarian cancer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prima
BioMed Ltd</B>, Level 7, 151 Macquarie Street, Sydney NSW 2000 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>www.primabiomed.com.au</U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ABN: 90 009 237 889 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g358641g57z91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358641g57z91.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#H!)@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`,+4_$UO::U;Z'9I]KU:<;_)4\0Q]Y)#_"/U/:@#9DFC
MMX#+<2I&BC+.QVJ/SZ4;%1BY.T5=F7;^*_#]U<?9X-9LWES@*)ADU"G%Z7.F
M>!Q,(\TJ;MZ">(-=_P"$=MEU"YMVDTU#BXDC&6@']\CNOKCD=>:LY#4MKF"]
MM8KFVF2:"50R2(<JP/<&@!9YX;6!Y[B5(H4&6=V"JH]230!GQ>)="FD$<6M6
M#N>BK<H2?UH`O7-Y;65NUQ=7$4$"XS)(X51GIR:`*,?B7097"1ZU8.QZ!;E"
M3^M`%^:X@M[=KB:9(X4&YI'8!0/4F@!MG>VFH0">RN8KF')&^)PZY'N*`&PZ
MA97%U-:P7<,MQ!_K(DD!9/J!R*`')>6LEY)9I<Q-<QJ&>$."Z@]"1U`H`GH`
MI+K.EO?FP34;5KP$J8!,I<$=1MSF@"[0`A(4$DX`ZDT`9/\`PE/A[./[=T[/
M_7TG^-`&G!<0W4*S6\R2Q-T=&#`_B*`(+/5=/U!Y$LKZWN6B^^(95<K]<'B@
M!UWJ%E8('O+N"V4]#-($!_.@"2WN8+N$36T\<T1Z/&P8'\10`V[O;33X#/>7
M,5M"#C?*X1<_4T`+-=VUO:&[FN(HK95W&5W`0#USTH`5[JWCM3=//&MN%WF4
ML`NWUSTQ0!F_\)5X>_Z#NG?^!2?XT`6QJVG'3_[0%_;?8A_RW\U?+ZX^]G'7
MB@"O'XET&9PD6M6#L>@6Y0D_K0!I@A@"I!!Z$4`#,L:,[L%51DDG``H`K66I
M6.I(SV%[!=(APS0R!P#Z'%`%23Q-H,4C1R:W8(Z$JRM<H"".Q&:`$7Q1X?=@
MJZYIY8G``N4R3^=`$MUK^C65PUO=:M903+]Z.2=58?4$T`6+34;&_4M97D%R
M!U,,@?'Y4`6:`.>\;^)X_!_A2[UAD$CQ[4BC/\3L<`?U_"@#CO@G92W6B:CX
MHOY#/J6JW+;Y6Z[5.,#T&<\>PIL#"^,.JWLGB&+2R[)910K(J#@.QSR?7IBN
M'$2=^7H?<\.8>DJ#K6]Z]O0\VKF/JCW?X6W]SK?@ZXM=2S<0Q2&!3)SO0J/E
M/KC.*[Z$FXZGYWG^'IT,5^[TNKLY?X6ZS-X<\=:QX!N)6>TBFD:RW'.S!R5'
ML5Y^H/K70>`>@_$<9^'&O@_\^CT@/%_"GP^\,:S\)KK7M19K6_B\XK<>;A05
M^Z-IX/IZTP(]+U2_U']G[7[>]D>:&TNHHX&D.2%+*2N?0'^=`#K;P;X%?X1Q
MZW>7:6VM&W=QBYRS2`G:OEY[X':@#H/"<VHS_L[ZY]O,C1+'*ML9,DF/`Z9[
M9SB@#HO@E/'9_"K[1(0L<4\[L?0#DT`>??"3Q#)+\6KNZN"5&LI,Q+<`G.\?
M^@D4`6_`OBE[[X[WFH,2+?56FMXR>A5<%!^2C\Z`/==>U>'0=`OM5N#B.UA:
M0CU('`_$X%(#Y;AM=6TJRTWXDLQ:2;4W+<=<'.<^A.\?A3`^K;"]AU+3K:^M
MFW07$:RH?4$9%(!UW_QY3_\`7-OY4`?,7PWT#P/JUEJ\GBVYBMWBD40EKGRC
MM(.2!W[4P.S^!$=U#K?B&*RDGE\/*<022`A68,=I'OMZX]J&!7^"-Q'8ZCXS
MNI!B.']XV/0,Y/\`*A@1>"/"2_%F^U/Q3XJGGFMO.,5O;I(54=\>P`(''6C8
M"8V$GPB^*&E6VG74S:!K!"-!(V0I)V_F"00?0XH`N?M":J?[.TG0XLLT[M<2
M*!GY5&!_,_E0@,KQCXJ:]^!?ARRC8O<:CMA=1R2(N"/S"T`=7IFI_P!J_L[3
M2LVYXM-D@?ZH"O\`("CJ!POPX\+_``\U7PH+GQ+<6\6H>>Z[9+SRCM&,?+D4
M`=]XZTO1](^!=_9Z%M;3`J-"5D\P$&922&[\F@#GO`_PD\+>*/A[I^HW<,\5
M_<(Y:>*4C!#$`[3QV%`$7PZU/6/!7Q*G\":E=M<V4A(A+$D*=NY67/0$=1ZT
M`>U:Q_R!+_\`Z]Y/_032`\G_`&=P!X;UC``_TI?_`$`4V`[XE?#+PMIWA/6]
M?MK%UU$?OO,,S$;F<9.,X[F@"K\,/AEX6USP9IFMWUB[WY=V+B9E&5D('`..
MPH`R=9T#3O$O[1=SI>J0F6TE0%E5BI.(01R/<4`6/'OPU7P#:1^*_!]W<6IL
MY%,L32%L#/!![C.`0<]:`/8O">NKXE\*:;K"J%-U"&=1T5QPP_!@:0'$_'JU
MFN/ATLL0)2VO8Y9<?W<,O\V%-`4_@)K]O=^%)]$+@75C*SA2>6C8YR/H<C\J
M&!W7BKP;IGBRW1;P-'/%_JYX_O+[>X]JRG34UJ>C@<QK8&5Z>SW1Q-O\$[=;
MC-QK4CP@_=2$*Q_')K%89=6>Y/B:HXVC32?J>BV5EIOAG11#`J6UC:H69F/0
M#DL3_6NF,5%61\Q7KU,14=2H[MGSSX(O9?%'QX&K6RD1/<37'TCVD#/YC\ZH
MQ/</B/\`\DYU_P#Z]'I`>0_#7X4:/XO\*0ZKJ-[?*3,Z&&*0*A"GZ4P.W^)6
MA:=X<^#5_IFE6RV]K$8\*.229%R2>Y/K0!YM-\-[&7X.6GB[3Q,-4C3SIP6R
MK*'(.!VP,'\#0!Z%!XC7Q-\`-0NVVBXALG@G50``ZC&<#ID8/XT`<GHVL?V-
M^S;?,K8EN;B2V3'J[`'_`,=S0!F^.=`N/!_A/P5JEF?)NHK=HI7`Y#."_P#[
M,PH`O:OH;>"/!OP_UG9LN+:\$MR>_P"\PV#]`N*`.E^.VN2-I6F>&;$F2YU.
M4.R)U90<*/Q8C\J$!SM_I?Q)N?`B^%I?"-HNG0QJ%9)`9!M.=P^;KGV[F@#K
M_@5XB.I>$)-(F;-QI<FP`]?+;)7\CD?A0P/3KO\`X\I_^N;?RI`?.7PG\-^$
M==LM9D\3I;%H95$337'E%00<XY'M3`Z/X2ZO-;?$+6?#>EWTM[X<A5WMR[;A
M&`P`*GT.2/?K0!1^#UHU^_CJS3[UQ&8Q]29!_6@#>^`NK01:#?\`AZX<1:A:
M73.8F.&*D`'`]B#FA@4OB7=1>)?BGX5T#3W6::TF#SE#G9E@2#]%7/XT`65M
M4\:?'75UE&^STFQ:VYY`9E*G]7;\J`.+^%>@W6J^/X--O\O9>'S,Y1AP'+8Q
M^+<_A0!O>%)FLOAW\0_#LAP^G/-M4_W2"/YK0!!\+_!O@C7?!XO/$$=N;[[0
MZ9DNC&=HQCC(H`[CXC6>G:?\$[^STDI]@@CC2+8^\`"5>,]Z`#X9>(-&TCX5
M:4^H:I:VPB1RXDE4$?.W;K0!P_ABZ?Q]\>'\0643C3K/YMY&/E5-JY]R><4`
M>Z:Q_P`@2_\`^O>3_P!!-(#Q_P"`&H65EX=U9;J\@@9KI2!)(%)&P>M-@=I\
M4+JWN_A7KLEM/',@C4;HW##.]>XI`1_!G_DENE?[TO\`Z,:FP.':>&V_:<EE
MGF2*-8^7D8*!^X]31T`V?C%X[T@>%I_#^G7<5[J%\50I`P?8N0>2.YQ@#K0@
M.V^'NBS>'O`6CZ9<@B>*$M(I_A9V+D?@6Q^%(#>OK&VU*QFLKR%9K>9=KHPX
M(H`^6O$FA:Y\)O&D=UI\SI#N+6=SC*R)W1O4]B/QI@>Z>`/B;I?C6V6!BMIJ
MZ+^\M6;[WJR'N/U%(#L-0U&STJQEO;^YCMK:(9>21L`"@#YN^)/Q4NO&$AT?
M1EDATC=M.`?,NCGC([#T'?O3`]1^$7P_?PCH[W^HQ[=6OE&]3_RQ3J$^O<__
M`%J`.\U?2[;6](NM,O`QMKF,QR!&P<'T-("IX:\-:=X3T==+TM9%ME=G`D?<
M<GKS0!)XAT"Q\3:+-I.HAS:S$%A&VT\$$<_A0`W3/#FG:3X;30+>-FT](FBV
M2-N)5LY!/XF@#%TGX:>']%T34]'LQ="RU)=LZ-.3VQD>AH`B/PL\--X?M-#*
M71L+6X-RB>><ESZGN/:@#=\1>&-+\4:=%8:I"SV\4JS*JMMPR]/PH`;XE\+:
M9XLT;^RM4C<VN]7`C?801TP:`,Z3X>:%-XDL=>G6XEO;%$2'?,2JA!A>/7O]
M:`.KH`Y?0?`&A^&M>O-8TQ)XKB[W"5#*3&<MNX7MSTH`Z:1!)&T;?=8$&@#S
M9O@1X)9LM!>$_P#7R:=P.O\`#7A#0_"-J\&C6*VXDQYCDEG?'3+'FD!6\,>!
MM%\(W5]<:4DRR7I!E\R4L."3QZ=30!C>*?A%X=\3ZFVIEKFPOG.9);5PN\^I
M!'7W%`&AX.^&^@>"GDGT^.6:\D&UKFX;<^/0=@*`-#P_X0TKPS>:E=V"RF?4
M9?-G>63>2<D\>@Y-`$VD>&-+T/4]4U"QA9+C4I1+<,6SD^WH.30!FGX?:%]N
MUR\"3B36HS'=@2G:P/4@=C_C0!SI^`_@@]8+P_\`;R:=P.E3P#H<?@IO"2I,
M-*8Y*^:=_P!_?][ZT@.=B^!7@>.4.UI=28[/<M@_E3N!W.C:%I?A^Q%GI-C%
M:6X.=L:XR?4GJ3]:0%RX@2YMI;>3.R5"C8..",&@#S<_`?P0>L%X?K<FG<#H
M++X=>'[#PA=^&((YQIMTY>13*2V>.A[?=%(#8\/:!8^&-%@TG30XM82Q02-N
M/))//U-`'->(/A-X6\3:S/JNI17+74^-^R<JO``''T%`$^@?"OPAX<NX[NRT
ML/<Q'='+.YD*'U&>`?>@#LJ`"@#,U[P_IOB729=,U2V6>WD_`J>S*>Q'K0!\
MZ^(/AG)X#UD:EJ&I,-$A;?#-`^RXD?\`AB4=F_VN@&3[4P.<U_Q5XA\?ZM;V
MT\KR!Y!':V:-A%)X'7J?]HT;`>W_``V^$=MX6,>JZQY=UK&,HHYCM_IZM[_E
M0!ZC2`*`"@`H`*`"@`Z4`'TH`*`"@!%96SM8'!P<'I0`M`!0`4`%`"$@=2!0
M``@]#F@!:`"@`H`*`"@`H`*`$#JQ(#`D=0#TH`6@`H`*`"@`H`*`"@`H`*`/
MG;XJ+J?C+XM6OA>T)VP*D<0/W5+#<[G\/Y4P*GQ+^%*>#=*M-8T>XFEMX]L=
MR7/S))VD'H">W8XH`]S\"ZO/KO@?1]2N>9YK<>8?5AP3^.,T@.AH`RO$NI-I
M'AR^O(P3,L>V(*,DNWRJ`._)%`'$>']7?0M-N]'LI)G%K?VPB:ZC96:&=U#<
M-@_>W\_2F!M:OKVM)?ZK:Z='YBVL]NA,,0DE2-HRS%5)&XYQQZ$]:0%"#4]3
MU75?#WE:T1MNIX;A/LAB8E8RV'1CPV"/;D$4`3C7]9.G75]-?PPA[^2RM88K
M4R.=LC#(&?F<A>G`&,F@"K_:]_?_`&:VOC)YMGKEO$&DC$3LI3<-RJ2,_-_*
M@!;37+YK2WM-/E\B9GN7:&SL_-?`G90QW$*J\<\Y)Z4`267B+7]<AC:VNK>R
MQI4=ZY,&\F0LX*XSPIV_6@"_XDU6YN/AQ'J$;FV:\CM_->,X,22,@<@]L!CS
M0`W4+#1?"+/>Z;<0Z7<?9740X+),`5PS(.68$@`CD[L4`9TOBK6[&UUF-][S
MVUI%<P-=VPA.6<J054GCCV/6@"[?:[K6BRW]C/<P7=P4MC;S&'8L;32F/Y@#
MR`1GU[4`&JZSKFC/;Z8US'>W-W<B..X@@!D1!&7;,><;OEP.>G/:@!@UOQ+*
M-/L,):W%S>R6_P!HN(`&:(1%P^P'`;MC..*`-#QYI=G>^#-2FO+=)Y[6TE>*
M1ARC;/O#T/%`&=:M-HVHII^DQV]GIL&GKJ%PJ19>5LD%1SQD*.?:@"+2O%&N
M206VHWD92RN;5YY'FMQ'%;?)O4A@Q+KV/&>_%`$#:_KDL5U9O=3K]HTR:YBG
MELQ"49-OW!NS@AOXN1Q0!>M;S7C!H^FPZI$LDNEM=27#P;F)&S:,9Q_%R:`(
M8/%>L6EE8ZK?/!/!>Z;->?9HH]OE-&BL`&SDY!.<T`)!XD\10Z=/=SPR2(=/
MEN=\ML(DAD5-RA?F)=3R.>>!ZT`)J6I:_'IE];SZE%YESH\EZDD4&TP,N,J.
M>00W!/(QF@#7U6ZU+3?AK=727)FOXK`NLP3:0=O7'J!_*@"C/IN@^%-.M=:L
MF\JY@MI'4(_-_B,L0Y_BZ;L]1B@".ZU_7-&@5[JZM[QKO39KN+9#L$,D:AL=
M?F4[L<\\>]`#I-0\3"ZGM!JEJK#3Q?B3[+G:<D>7C/*\=>M``-=U[56G:RN[
M6S2#3(+[:\._<[JQ*GGA?EZ]:`*5_P"--3DT^74]/D;9;VD5P]O':;T0L@<K
M)(Q&.#_#R!@T`7M4UW7$EUVZM;FWAM=)CBE6)H=QFS&'92<\#T(]:`+EMXBO
M9=;_`+$8Q_;4O"6.W_EUV[PV/7D)GUS0!UE`!0`4`<CJ'A,1_$"Q\76:AI5B
M:VNHN[(1PZ^XZ$=Q0!<\:Z-<>)/#4^AV^$^VE4DF8<1(&!+>YXX'J:`-;2M,
MMM&TFTTVS39;VL:QH.^`._O0!<H`@N;.WO/)%Q&'$,BRH">C#H?PH`J:AH&F
M:I)))>6HDDDA\EFW$':&W`<'LPR#U%`%0>#]$6&2,6K!I)%E:7SG\PNHP&WY
MSG!(SF@"0>%M)6VBA6!U\J8SK*)G$GF$8+%\Y)(X.3TH`EF\.Z7/8_8VM]L0
MG-PNQV5ED+%BP8'(.2>GK0`RW\,Z1:#]U:8/GK<EF=F+2J,!R2>3B@!DGA/1
MI#&1:M&4WC,<KIN5F+,K8/(+$G!H`L6>@:7IZ;+6T6)?(%M@$\1@DA?I\Q_.
M@"P-.LQI8TPVZ-9"+R?)8979C&.?:@#+A\&Z%!!<0_8S(L\8B8S2O(0@.0JE
MB2H!YXQTH`>GA/1D6X#6K2M<QK',\LKNTB@Y`))SP:`+EYHNG7[7#75JLIN(
M1!+DGYD!)`]L$DYZT`5!X3T<63VIMG8/*)C*TKF7>!@-OSNR!P.>E`$]KX?T
MRS%MY-MAK>1ID=F+-O8$,Q).22"1S0!<O+2"_LI[.ZC$EO.ACD0\;E(P10`R
M/3;2*[^U)"!-Y(@W?[`.0OZT`9UOX1T2V9REEN1D>,1R.SHBM]Y54G"@^U`#
MK3PKI%E,)H[9GE$30!YI6D(C.,I\Q/'`XH`FL?#^G:=Y7V>)\Q1M#&7D9RJ$
M@E1D].!^5`#X]#TV%+-$M4V6<30P`Y(1&`!'OD`=:`*EMX1T6U2:..T8I+"U
MOM>5W"1MU1<GY0?08H`NR:182LK26RL5MVMAG/\`JCC*_3@4`/L=-MM/L%LH
M0[6Z@J%E<R<>F6SQ[4`9]AX2T739_.MK/D(8T621G6-#U5%8D*#Z"@`MO"6B
MVD4\4=H2DT)MR'E9]L1ZHN3\J^PH`OG2K(S-,8!YC0?9B<G_`%?]W]:`,.3P
M/ID^J33SH3:M:PVL<*.Z81-V5)!^92".#Z4`7;SPCHE]+,T]GE9U"2Q+(RQR
M`#"[E!P2!@#Z"@"W)HFG217L;VP9+U0EP,GYP%V@?EQ0!6L-&DBU^\UB[,#3
MR1+;0B)"-D*DD`D]22>?H*`-F@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
J@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
